Page last updated: 2024-11-04

dihydrocytochalasin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dihydrocytochalasin B (DHCB) is a fungal metabolite produced by the fungus *Phomopsis longicolla*. It is a potent inhibitor of actin polymerization, which is a critical process for cell motility, division, and other cellular functions. DHCB has been extensively studied for its potential as an anti-cancer agent. It has shown promising activity against various cancer cell lines, including leukemia, melanoma, and breast cancer. DHCB has also been investigated for its ability to inhibit the growth of parasitic protozoa. The synthesis of DHCB involves a complex multi-step process that utilizes a variety of organic reactions and reagents. DHCB's effects are primarily attributed to its ability to bind to and disrupt actin filaments. This disruption leads to a variety of cellular changes, including inhibition of cell migration, cytokinesis, and endocytosis.'

dihydrocytochalasin B: inhibits cell motility in many eucaryotic cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3064
MeSH IDM0083392

Synonyms (3)

Synonym
dihydrocytochalasin b
39156-67-7
cytochalasin h2b

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, anti-immunoglobulin in combination with cytochalasin B stimulated substantial proliferation as judged by [3H]thymidine incorporation."( Anti-immunoglobulin in combination with cytochalasin stimulates proliferation of murine B lymphocytes.
Rothstein, TL, 1985
)
0.27
" In contrast, TERT expression combined with β-HPV 8E6 expression allowed cells to proliferate for months following cytokinesis failure."( β-HPV 8E6 combined with TERT expression promotes long-term proliferation and genome instability after cytokinesis failure.
Dacus, D; Riforgiate, E; Wallace, NA, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies, also reported here, indicate that the detergent insolubility of the complexes does not correlate with secretion."( Antigen-dependent transition of IgE to a detergent-insoluble form is associated with reduced IgE receptor-dependent secretion from RBL-2H3 mast cells.
Oliver, JM; Seagrave, J, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (39.24)18.7374
1990's30 (37.97)18.2507
2000's12 (15.19)29.6817
2010's4 (5.06)24.3611
2020's2 (2.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.48 (24.57)
Research Supply Index4.42 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other82 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]